Regional Variation and Clinical Indicators of Antipsychotic Use in Residential Treatment: A Four-state Comparison

Journal of Behavioral Health Services and Research

Volumn 31, Issue 2, 2004, Pages 178-188

  Rawal, Purva H ^a   Lyons, John S ^a   MacIntyre II, James C ^b,c   Hunter, John C ^d  

^a NORTHWESTERN UNIVERSITY   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

^c NEW YORK STATE OFFICE OF MENTAL HEALTH   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

AGGRESSION; ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; CHILD HEALTH CARE; CLINICAL MEDICINE; COMPARATIVE STUDY; CRIMINAL BEHAVIOR; DRUG USE; HEALTH CARE PLANNING; HUMAN; IMPULSIVENESS; MENTAL DISEASE; PREDICTION; PRESCRIPTION; PSYCHOSIS; REVIEW; SEXUAL ABUSE; STATISTICAL ANALYSIS; TREATMENT INDICATION;

EID: 1942469582     PISSN: 10943412     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf02287380     Document Type: Review

References (26)

1. Gracious BL, Findling RL. Antipsychotic medications for children and adolescents. Pediatric Annals. 2001;30:138-145.
2. Gadow KD. An overview of three decades of research in pediatric psychopharmacoepidemiology. Journal of Child and Adolescent Psychopharmacology. 1997;7:219-236.
3. Jensen PS, Bhatara VS, Vitiello B, et al. Psychoactive medication prescribing practices for US children: gaps between research and practice. Journal of the American Academy of Child and Adolescent Psychiatry. 1999;38(5):557-565.
4. Kelleher KJ, Hohmann AA, Larson DB. Prescription of psychotropics to children in office-based practice. American Journal of Diseases of Children. 1989;143:855-859.
5. Pincus HA, Tanielian TL, Marcus SC, et al. Prescribing trends in psychotropic medications: primary care, psychiatry and other medical specialties. Journal of the American Medical Association. 1998;279(7):526-531.
6. Hoagwood K, Jensen PS, Feil M, et al. Medication management of stimulants in pediatric practice settings: a national perspective. Journal of developmental & Behavioral Pediatrics. 2000;21:322-331.
7. Green WH. Child and Adolescent Clinical Psychopharmacology. 3rd ed. Philadelphia, Pa: Lippincott; 2001.
8. Connor DF; Ozbayrak KR, Harrison RJ, et al. Prevalence and patterns of psychotropic and anticonvulsant medication use in children and adolescents referred to residential treatment. Journal of the American Academy of Child and Adolescent Psychopharmacology. 1998;8(1):27-38.
9. Riddle MA, Kastelic EA, Frosch E. Pediatric psychopharmacology. Journal of Child Psychology & Psychiatry & Allied Disciplines. 2001;42(1):73-90.
10. Findling RL, McNamara NK, Branicky LA, et al. A double blind pilot study of Risperidone in the treatment of conduct disorder. Journal of the American Academy of Child and Adolescent Psychiatry. 2000;39(4):509-516.
11. Frazier JA, Meyer MC, Biederman J, et al. Risperidone treatment for juvenile bipolar disorder: a retrospective chart review. Journal of the American Academy of Child and Adolescent Psychiatry. 1999;38(8):960-965.
12. Findling RL, Schulx SC, Reed MD, et al. The antipsychotics: a pediatric perspective. Child and Adolescent Pharmacology. 1998;45(5):1205-1233.
13. Schereier HA. Risperidone for young children with mood disorders and aggresive behavior. Journal of Child and Adolescent Psychopharmacology. 1998;8(1):49-59.
14. Kaplan SL, Simms RM, Busner J. Prescribing patterns of outpatient child psychiatrists. Journal of the American Academy of Child and Adolescent Psychiatry. 1994;33(1):35-44.
15. US Surgeon General. Report of the United States Surgeon General's Conference on Children's Mental Health: A National Action Agenda. Washington, DC: Department of Health and Human Services; 2001.
16. Maislin G, Choudhury MS, Gifford C, et al. Risperidone treatment in children and adolescents with autism: short- and long-term safety and effectiveness. Journal of the American Academy of Child & Adolescent Psychiatry. 2002;41(2):140-147.
17. Turgay A, Binder C, Snyder R, et al. Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. Pediatrics. 2002;110(3):e34.
18. McCracken JT, McGough J, Shah B, et al. Risperidone in children with autism and serious behavioral problems. New England Journal of Medicine. 2002;347(5):314-321.
19. Vitiello B. Pediatric psychopharmacology and the interaction between drugs and the developing brain. Canadian Journal of Psychiatry. 1998;43:582-584.
20. Lyons JS, Sokol PT, Lee M, et al. The Child and Adolescent Needs and Strengths for children and adolescents with mental health challenges (CANS-MH). 2001. Available at: www.buddinpraed.org.
21. Anderson R, Lyons J, Giles D, et al. Examining the Reliability of the Child and Adolescent Needs and Strengths-Mental Health (CANS-MH) Scale from two perspectives: a comparison of clinician and researcher ratings. Journal of Child and Family Studies. 2003;12(3):279-289.
22. Schur SB, Sikich L, Findling RL, et al. Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY), Part I: a review. Journal of the American Academy of Child & Adolescent Psychiatry. 2003;42(2):132-144.
23. Pappadopulos E, Macintyre Li JC, Crismon ML, et al. Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY), Part II. Journal of the American Academy of Child & Adolescent Psychiatry. 2003;42(2):145-161.
24. Campbell M, Rapoport JL, Simpson GM. Antipsychotics in children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry. 1999;38(5):537-545.
25. Sirio CA, Jones J, Webster G, et al. Assessing regional variation in cesarean birth and vaginal birth after cesarean rates in a major metropolitan area: improving health service delivery. Obstetrics & Gynecology. 2000;94(4 suppl 1):S78.
26. Goodwin R, Madelyn S, Gould CB, et al. Prescription of psychotropic medications to youths in office-based practice. Psychiatric Services. 2001;52:1081-1087.